In different investigations, the mortality rate due to MDR
Pseudomonas and
Acinetobacter infections among burn patients has been reported as 30 to 38%. In comparison to this high mortality rate reported in the literature, the survival of our case is notable and wonderful (
5). In a study by Azimi et al., it was shown that comorbidity of
Pseudomonas and
Acinetobacter infection causes longer hospital stay and increased mortality in burn patients (
6). The most reliable predictor of outcome of pediatrics burns is the percentage of TBSA burned, followed by depth. The enormous progress in burn treatment is attributable to the multiple factors including knowledge of the pathophysiology of burns, recognition of the importance of nutritional needs, use of topical agents/novel dressing/systemic antibiotics, increasing in immune system and early debridement/grafting techniques. For a child with a disrupted mechanical barrier and suppressed immune system, any organism is a potential pathogen (
7).
Multi-drug resistant
Pseudomonas and
Acinetobacter species are defined as resistant to at least three classes of antibiotics. The number of organisms present on the burn wound, organism's unique virulence, invasiveness and motility affect pathogenicity. In a study by Goverman et al., they identified 14 children infected with pan-resistant gram negative organisms that were treated by 16 courses of Colistin. 12 (85.7%) cases had a favorable response to therapy; however 2 (14.3%) cases died due to sepsis (
8). Ferreira et al. reported that nowadays resistance in
Pseudomonas and
Acinetobacter species have been a growing problem in burn patients and antibacterial therapy has been frequently associated with resistance. Also they indicated that prevention of cross-transmission is an important factor in controlling resistance for these patients (
9).
The patient's blood cultures with BACTEC method showed
Pseudomonas aeruginosa that was resistant to Aztreonam, Cefepime, Amikacin and Ciprofloxacin. The isolate was sensitive to Tobramycin, Meropenem and Colistin. Colistin is a polypeptide antibiotic of the Polymixin group that is rapidly bactericidal to gram negative bacteria. This drug has a detergent-like mechanism interfering with the outer cytoplasmic membrane of the bacteria. Colistin remains active against almost all strains of
Pseudomonas and
Acinetobacter. Acquired resistance is rare. Colistin seems to be a safe drug in selected cases of infections with MDR gram negative micro-organisms (
10). In a study by Tamma et al., they found out that Colistin application was safe. Although there was some evidence of nephrotoxicity and neurotoxicity in some patients, but these adverse effects are reversible and rare (
11).
In the study by Keen et al., it was reported that percentage of TBSA and other clinical parameters have influence on empiric antibiotic therapy and management of patients with multidrug resistant
Pseudomonas and
Acinetobacter (
12).
Systemic antibiotics are only used when systemic infection is strongly suspected, but its role is adjunctive and it never replaces surgical debridement, use of topical agents, nutritional support, increasing in immune system function (IVIG/G-CSF/IFN-γ) and grafting. Evidence in the published literature suggests that this combination therapy is effective for burned patients with MDR gram negative sepsis (
13).
Considering the present study, it is believed that an early diagnosis of the wound infection, administration of the appropriate systemic and topical antibiotics, early excision and grafting, adoption of infection control and prevention standards like proper hand hygiene, isolation rooms, environmental cleanliness and disinfection methods may significantly reduce infections caused by MDR micro-organisms in burn units. Also the pattern of resistance to antibiotics is an important factor in treatment, and using new antibiotics can be useful.